The joint venture, Paradigm, is being formed under the Michigan Health Corporation, an arm of UMHS that enables outside partnerships. Paradigm will offer whole gene and multi-gene sequencing and molecular diagnostics to providers across the country and will also help support various clinical trials.
“Pursuing new, innovative channels for scientific collaboration is a priority and strength of the University of Michigan,” said Ora Pescovitz, MD, CEO of the U-M Health System and U-M executive vice president for medical affairs, in a statement. “Paradigm is a terrific example of this effort and of how cutting-edge science will have an immediate benefit for patients.”
More Articles on University of Michigan Health System:
University of Michigan Health Launches New Oncology Research Program
University of Michigan Health Program Reduces Readmissions
University of Michigan Health Adds 14 Cardiologists to Meet Outpatient Demand
